Boughton Soleil 4

What Happened

• Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc. (HIMS), received an award of 188,111 restricted stock units (RSUs) on 2026-03-11. The grant is reported as a derivative award (Code A) at $0.00 per unit — RSUs are a contingent right to receive one share of Class A common stock per RSU upon vesting. This was a compensation award (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-03-11; Filing date: 2026-03-13 (filed within standard Form 4 timing).
• Award amount and price: 188,111 RSUs; reported acquisition price $0.00 (no cash paid at grant).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Vesting: Service-based over 4 years in substantially equal quarterly installments on March 15, June 15, September 15 and December 15, starting June 15, 2026 (see footnote).
• Footnotes: F1 clarifies each RSU converts to one share when vested; F2 describes the quarterly 4-year vesting schedule.
• Transaction type: Code A (award/grant). This is a derivative grant (RSUs), not an immediate share transfer or sale.

Context

• RSU grants are typically compensation/retention tools; value is realized only as RSUs vest and convert to shares, and depends on HIMS’s share price at vesting. This award is not an immediate market purchase or sale and does not by itself indicate insider buying or selling intent. Tax withholding or share retention requirements may apply at vesting (not detailed in this filing).